We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$224K
AUM Growth
-$183M
Cap. Flow
+$30.6M
Cap. Flow %
13,629.74%
Top 10 Hldgs %
33.66%
Holding
127
New
36
Increased
38
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.26M
2
MGNX icon
MacroGenics
MGNX
+$5.18M
3
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.94M
4
VCYT icon
Veracyte
VCYT
+$3.89M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$3.65M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.78M
2
CRIS icon
Curis
CRIS
+$4.17M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.01M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.36M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.44%
2 Financials 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
26
CALL
Seres Therapeutics
MCRB
$47M
$2.93K 1.31%
+6,135
New +$2.59M
ADMS
27
DELISTED
Adamas Pharmaceuticals
ADMS
$2.85K 1.27%
538,744
+16,155
+3% +$83.6K
UTHR icon
28
United Therapeutics
UTHR
$26.3B
$2.74K 1.22%
15,289
+9,925
+185% +$1.89M
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.71K 1.21%
139,305
+4,624
+3% +$84K
DNAB
30
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$2.53K 1.13%
+250,000
New +$2.53M
PROK icon
31
ProKidney
PROK
$316M
$2.53K 1.13%
+250,000
New +$2.53M
AKLI
32
DELISTED
Akili Inc
AKLI
$2.53K 1.13%
+250,000
New +$2.53M
DNAD
33
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$2.52K 1.13%
+250,000
New +$2.52M
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.69B
$2.42K 1.08%
234,020
+5,535
+2% +$56.2K
NXTC icon
35
NextCure
NXTC
$20.8M
$2.29K 1.02%
+23,792
New +$2.43M
ALDX icon
36
Aldeyra Therapeutics
ALDX
$95.6M
$2.18K 0.97%
192,345
-129,534
-40% -$1.56M
EYPT icon
37
EyePoint Inc
EYPT
$1.04B
$2.18K 0.97%
242,309
-57,691
-19% -$554K
OTIC
38
DELISTED
Otonomy, Inc.
OTIC
$2.13K 0.95%
953,434
+702,439
+280% +$1.62M
CRIS icon
39
Curis
CRIS
$9.14M
$2.09K 0.93%
649
-923
-59% -$4.17M
BNTC icon
40
Benitec Biopharma
BNTC
$398M
$1.99K 0.89%
+27,486
New +$2.15M
CGEM icon
41
Cullinan Oncology
CGEM
$1.07B
$1.95K 0.87%
+75,732
New +$2.33M
VTGN icon
42
VistaGen Therapeutics
VTGN
$9.45M
$1.94K 0.86%
+20,518
New +$1.52M
ITOS
43
DELISTED
iTeos Therapeutics
ITOS
$1.94K 0.86%
+75,511
New +$1.8M
ZNTL icon
44
Zentalis Pharmaceuticals
ZNTL
$321M
$1.85K 0.82%
+34,725
New +$1.86M
CGEN icon
45
Compugen
CGEN
$225M
$1.73K 0.77%
209,113
+134,113
+179% +$1.09M
KURA icon
46
Kura Oncology
KURA
$901M
$1.72K 0.77%
82,573
+2,573
+3% +$63.9K
AFMD
47
DELISTED
Affimed
AFMD
$1.72K 0.77%
20,219
-30,014
-60% -$2.74M
JNCE
48
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.7K 0.76%
250,644
-99,356
-28% -$825K
MRSN
49
DELISTED
Mersana Therapeutics
MRSN
$1.7K 0.76%
5,005
+4,005
+401% +$1.52M
RCUS icon
50
PUT
Arcus Biosciences
RCUS
$3.5B
$1.66K 0.74%
+60,400
New +$1.73M
1
2
3 4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Silverarc Capital Management held 127 positions worth $224K, down 100% from $183M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Silverarc Capital Management deployed $30.6M of net new capital in Q2 2021, opening 36 new positions and adding to 38 existing holdings. Its largest new stake was MacroGenics: 176,915 shares worth $4.75K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Curis, an estimated $4.17M trimmed.

  • Silverarc Capital Management's largest Q2 2021 buy was MacroGenics: 176,915 shares worth $4.75K.
  • Silverarc Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.26M increase.
  • Silverarc Capital Management's biggest Q2 2021 reduction was Curis, cutting an estimated $4.17M.
  • Silverarc Capital Management fully exited Vericel Corp in Q2 2021, selling an estimated $6.78M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $224K portfolio in Q2 2021.
  • Silverarc Capital Management opened 36 new positions and closed 31 in Q2 2021.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $224K.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.